Vonjo (Pacritinib Citrate) Patent Expiration, LOE Window & CMS Spending
Vonjo (Pacritinib Citrate) by Sobi: FDA Orange Book core substance LOE 2030-03-25, 0 AB generics, $116.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sobi |
| FDA Application & Pathway | N208712 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2030-03-25 |
| Last Listed Patent or Exclusivity Date | 2030-03-25 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $116.3M |
| 2024 Medicare Part D Spend | $110.8M |
| 2024 Medicaid Spend | $5.5M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 32.7% 2-yr change) |